Skip to main content

Table 1 Clinical characteristics of MS patients and controls

From: Excitability decreasing central motor plasticity is retained in multiple sclerosis patients

Patient no.

Age* (years)

Sex*

Duration of MS (years)

Clinical subtype

Current DMT

EDSS

Control no.

Age (years)

Sex

1

23

m

4

RRMS

(FTY/Plac)

2.0

1

26

m

2

23

m

7

RRMS

FING

2.0

2

27

m

3

32

m

9

RRMS

IF

1,0

3

27

m

4

32

m

6

RRMS

GA

0.0

4

33

m

5

34

m

4

RRMS

NAT

3.5

5

35

m

6

48

m

3

RRMS

IF

2.0

6

45

m

7

23

f

6

RRMS

NAT

1.5

7

24

f

8

25

f

6

RRMS

IF

1.5

8

26

f

9

25

f

8

RRMS

IF

1.5

9

26

f

10

28

f

7

RRMS

IF

2.0

10

26

f

11

29

f

1

RRMS

IF

1.0

11

26

f

12

31

f

3

RRMS

IF

1.0

12

28

f

13

33

f

9

RRMS

IF

2.5

13

33

f

14

36

f

9

RRMS

IF

1.5

14

45

f

Mean

30.1

 

5.9

 

Median

1.5

Mean ±

30.5

 

± SD

± 6.8

 

± 2.5

 

[range]

[0–3.5]

SD

± 6.9

 
  1. *Patients listed by gender and age.
  2. m = male; f = female; EDSS = expanded disability status scale; RRMS = Relapsing-Remitting MS; SPMS = Secondary Progressive MS; DMT = disease modifying therapy with immunomodulators; FING = fingolimod; GA = glatiramer acetate; IF = interferon beta; MIT = mitoxantrone; NAT = natalizumab; (FTY/Plac) = fingolimod or placebo; patient participated in a randomized controlled treatment trial with undisclosed allocation.